CYP46A1 Activation Improves Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity
View abstract on PubMed
Summary
This summary is machine-generated.Activating CYP46A1 (cytochrome P450 46A1) with efavirenz reduced abnormal blood vessel growth and improved cell survival in developing mouse retinas with oxygen-induced retinopathy (OIR). This highlights a potential therapeutic target for retinal diseases.
Area Of Science
- Ophthalmology
- Neuroscience
- Biochemistry
Background
- The role of CYP46A1 (cytochrome P450 46A1) in the developing retina remains uncharacterized, despite its known metabolic and regulatory functions in adult retinas.
- Oxygen-induced retinopathy (OIR) is a significant cause of vision loss, characterized by pathological neovascularization and retinal damage.
Purpose Of The Study
- To investigate CYP46A1 expression and the effects of its pharmacological activation in the developing mouse retina.
- To assess the therapeutic potential of CYP46A1 activation in mitigating OIR-induced retinal pathologies.
Main Methods
- Developing C57BL/6J mice (P7-P17) were subjected to OIR and treated with efavirenz (EFV), a CYP46A1 activator.
- Retinal morphology, neovascularization, hypoxic areas, Müller cell and microglia activation, and retinal ganglion cell survival were analyzed.
Main Results
- EFV treatment significantly reduced pathological neovascularization and hypoxic areas in OIR mouse retinas.
- EFV administration limited reactive gliosis, microglia activation, and enhanced retinal ganglion cell survival.
- CYP46A1 expression and its metabolite 24-hydroxycholesterol (24HC) levels were found to be dysregulated in OIR retinas.
Conclusions
- CYP46A1 is developmentally regulated, and its activation shows promise in treating OIR.
- Pharmacological activation of CYP46A1 may offer a novel therapeutic strategy for pathological neovascularization in the developing retina.

